Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio
RA CAPITAL MANAGEMENT, L.P. Performance:
2024 Q3: 7.49%YTD: 14.71%2023: -2.79%
Performance for 2024 Q3 is 7.49%, and YTD is 14.71%, and 2023 is -2.79%.
About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings
RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in BOSTON, MA. On 03-Apr-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.7 Billions. In it's latest 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $8.7 Billions as of 30 Sep, 2024.
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, JANX. The fund has invested 16.7% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 11.4% of portfolio in VAXCYTE INC.
The fund managers got completely rid off LONGBOARD PHARMACEUTICALS IN (LBPH), UROGEN PHARMA LTD (URGN) and NURIX THERAPEUTICS INC (NRIX) stocks. They significantly reduced their stock positions in REGULUS THERAPEUTICS INC (RGLS), AN2 THERAPEUTICS INC (ANTX) and ENLIVEN THERAPEUTICS INC. RA CAPITAL MANAGEMENT, L.P. opened new stock positions in BICARA THERAPEUTICS INC, IDEAYA BIOSCIENCES INC (IDYA) and XENCOR INC (XNCR). The fund showed a lot of confidence in some stocks as they added substantially to NUVALENT INC-A (NUVL), BIOGEN INC (BIIB) and AVIDITY BIOSCIENCES INC (RNA).
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, JANX. The fund has invested 16.7% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 11.4% of portfolio in VAXCYTE INC.
The fund managers got completely rid off LONGBOARD PHARMACEUTICALS IN (LBPH), UROGEN PHARMA LTD (URGN) and NURIX THERAPEUTICS INC (NRIX) stocks. They significantly reduced their stock positions in REGULUS THERAPEUTICS INC (RGLS), AN2 THERAPEUTICS INC (ANTX) and ENLIVEN THERAPEUTICS INC. RA CAPITAL MANAGEMENT, L.P. opened new stock positions in BICARA THERAPEUTICS INC, IDEAYA BIOSCIENCES INC (IDYA) and XENCOR INC (XNCR). The fund showed a lot of confidence in some stocks as they added substantially to NUVALENT INC-A (NUVL), BIOGEN INC (BIIB) and AVIDITY BIOSCIENCES INC (RNA).
RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of 7.49% in the last quarter. In trailing 12 months, it's portfolio return was 31.02%.
New Buys
| Ticker | $ Bought |
|---|---|
| bicara therapeutics inc | 177,169,000 |
| artiva biotherapeutics inc | 152,234,000 |
| bioage labs inc | 45,980,300 |
| ideaya biosciences inc | 42,680,900 |
| mbx biosciences inc | 39,264,500 |
| xencor inc | 11,563,200 |
| avalo therapeutics inc | 9,186,500 |
| cidara thereapeutics inc | 7,558,110 |
New stocks bought by RA CAPITAL MANAGEMENT, L.P.
Additions
| Ticker | % Inc. |
|---|---|
| nuvalent inc-a | 47.16 |
| biogen inc | 20.6 |
| avidity biosciences inc | 16.67 |
| arcellx inc | 15.43 |
| rxsight inc | 6.01 |
| vaxcyte inc | 5.92 |
| dyne therapeutics inc | 5.49 |
| gh research plc | 1.29 |
Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| regulus therapeutics inc | -87.73 |
| an2 therapeutics inc | -63.97 |
| enliven therapeutics inc | -50.00 |
| praxis precision medicines i | -38.33 |
| third harmonic bio inc | -37.00 |
| verona pharma plc - adr | -34.37 |
| geron corp | -30.12 |
| lexeo therapeutics inc | -18.75 |
RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cybin inc | -11,925,200 |
| longboard pharmaceuticals in | -88,904,900 |
| urogen pharma ltd | -51,740,000 |
| unicycive therapeutics inc | -1,319,000 |
| macrogenics inc | -8,848,590 |
| nurix therapeutics inc | -13,565,500 |
RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks
Sector Distribution
RA CAPITAL MANAGEMENT, L.P. has about 63.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 63.7 |
| Others | 34.5 |
| 1.8 |
Market Cap. Distribution
RA CAPITAL MANAGEMENT, L.P. has about 2.8% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 36.1 |
| MID-CAP | 35.5 |
| SMALL-CAP | 21.8 |
| MICRO-CAP | 3.4 |
| LARGE-CAP | 2.8 |
Stocks belong to which Index?
About 54.9% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 52.3 |
| Others | 45.1 |
| S&P 500 | 2.6 |
RA CAPITAL MANAGEMENT, L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P. has 81 stocks in it's portfolio. About 55.2% of the portfolio is in top 10 stocks. PEPG proved to be the most loss making stock for the portfolio. PCVX was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABOS | acumen pharmaceuticals inc | 0.43 | 14,932,100 | 37,031,500 | unchanged | 0.00 | ||
| ACET | adicet bio inc | 0.12 | 7,541,000 | 10,859,000 | unchanged | 0.00 | ||
| ACLX | arcellx inc | 1.78 | 1,851,480 | 154,617,000 | added | 15.43 | ||
| ANTX | an2 therapeutics inc | 0.03 | 2,000,000 | 2,140,000 | reduced | -63.97 | ||
| ARVN | arvinas inc | 0.12 | 421,348 | 10,377,800 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 0.65 | 5,105,210 | 56,208,400 | added | 1.22 | ||
| AVTE | aerovate therapeutics inc | 0.22 | 9,192,090 | 19,211,500 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.11 | 967,000 | 9,186,500 | new | |||
| AXSM | axsome therapeutics inc | 1.04 | 1,000,000 | 89,870,000 | unchanged | 0.00 | ||
| BCYC | bicycle therapeutics plc-adr | 0.59 | 2,253,000 | 50,985,400 | unchanged | 0.00 | ||
| BIIB | biogen inc | 2.65 | 1,184,460 | 229,595,000 | added | 20.6 | ||
| CCCC | c4 therapeutics inc | 0.32 | 4,878,000 | 27,804,600 | unchanged | 0.00 | ||
| CDTX | cidara thereapeutics inc | 0.09 | 703,080 | 7,558,110 | new | |||
| CMRX | chimerix inc | 0.09 | 8,800,000 | 8,184,000 | unchanged | 0.00 | ||
| CYBN | cybin inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DAWN | day one biopharmaceuticals i | 1.26 | 7,871,720 | 109,653,000 | unchanged | 0.00 | ||
| DYN | dyne therapeutics inc | 2.64 | 6,381,140 | 229,211,000 | added | 5.49 | ||
| ELYM | climb bio inc | 1.84 | 31,419,300 | 159,924,000 | unchanged | 0.00 | ||
| ETNB | 89bio inc | 1.21 | 14,175,400 | 104,898,000 | unchanged | 0.00 | ||
| EVH | evolent health inc - a | 2.78 | 8,514,860 | 240,800,000 | unchanged | 0.00 | ||